AfshinSalsaliMD

Endocrinology • New Brunswick, NJ

Diabetes, Lipid Metabolism

Physician

Join to view full profile

Dr. Salsali is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Salsali's full profile

Already have an account?

Office
125 Paterson St
Ste 5200
New Brunswick, NJ 08901
Phone+1 732-235-7219

Education & Training

University of Vermont Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2001 - 2003
Quinnipiac University Frank H. Netter MD School of Medicine/St Vincent's Medical CenterResidency, Internal Medicine, 1998 - 2001
Tehran University of Medical Sciences School of MedicineClass of 1991

Certifications & Licensure

ND State Medical License Current
NJ State Medical License 2008 - 2025
VT State Medical License 2001 - 2012

Awards, Honors, & Recognition

Fellow (FACE) American Association of Clinical Endocrinology

Publications & Presentations

PubMed

52 citations
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
Wolfram Doehner, Stefan D Anker, Javed Butler, Faiez Zannad, Gerasimos Filippatos
European Heart Journal. 2022-09-21
14 citations
Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF.
Javed Butler, Muhammad Shahzeb Khan, JoAnn Lindenfeld, William T Abraham, Gianluigi Savarese
JACC. Heart Failure. 2022-09-01
65 citations
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial.
Mikhail N Kosiborod, Christiane E Angermann, Sean P Collins, John R Teerlink, Piotr Ponikowski
Circulation. 2022-07-26

Journal Articles

Empagliflozin Compared with Glimepiride in Metformin‐Treated Patients with Type 2 Diabetes: 208‐Week Data from a Masked Randomized Controlled Trial
Afshin Salsali, MD, Diabetes, Obesity and Metabolism

Press Mentions

Empagliflozin Lowers High Blood Pressure, Blood Sugar in DiabeticsJune 23rd, 2014